Compare Ionis Pharmaceuticals Inc. Common Stock (IONS) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ionis Pharmaceuticals Inc. Common Stock vs Xylem, Inc. — how do they compare? Ionis Pharmaceuticals Inc. Common Stock trades at $43.2 (market cap $7.04B), while Xylem, Inc. trades at $103.51 (market cap $23.94B). The key difference: Xylem, Inc. is far larger — about 3.4× Ionis Pharmaceuticals Inc. Common Stock's market cap, and Xylem, Inc. pays a 1.68% dividend while Ionis Pharmaceuticals Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ionis Pharmaceuticals Inc. Common Stock for 0 Days and Xylem, Inc. for 51 Days on average.
| IONS | XYL | |
|---|---|---|
Market Cap | $7.04B | $23.94B |
Volume | 2,977,440 | 1,097,519 |
Sector | Health | Industrials |
52-Week High | $86.50 | $152.95 |
52-Week Low | $42.38 | $100.92 |
Typical Hold Time | 0 Days | 51 Days |
Enterprise Value | $6.60B | $25.72B |
Dividend Yield | — | 1.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Xylem (XYL) trades at $102.74, showing modest daily gains of 0.15%. The stock demonstrates strong fundamental performance with consistent earnings beats and revenue growth from $5.5B in 2022 to $9.0B in 2025. Technical indicators signal bearish momentum despite neutral oscillators, with key support at $101. Recent developments include strategic acquisitions of Cornell Pump and Roper Pump, strengthening the company's industrial water solutions portfolio.
Xylem presents a compelling investment case with solid profitability (11.15% net margin) and analyst consensus target of $146.63 offering 43% upside potential. However, technical weakness and China market challenges pose near-term risks. The company's focus on water infrastructure and digital solutions positions it well for long-term growth in essential water technology markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Ionis Pharmaceuticals Inc. Common Stock
Ionis Pharmaceuticals Inc. is a biopharmaceutical company that develops RNA-targeted medicines using its antisense technology, with marketed treatments in neurology and cardiometabolic disease.
Read more on IONS →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
